New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
04:55 EDTBAX, BAX, BAX, LH, LH, LH, ACT, ACT, ACT, HUM, HUM, HUM, UNH, UNH, UNH, THOR, THOR, THOR, HSIC, HSIC, HSIC, VRTX, VRTX, VRTX, CNC, CNC, CNC, BSX, BSX, BSX, HNT, HNT, HNTBarclays to hold a conference
Healthcare Conference is being held in Miami, Florida on March 11-13.
News For BAX;BSX;CNC;VRTX;HSIC;THOR;UNH;HUM;ACT;LH;HNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 22, 2015
08:15 EDTUNHUnitedHealth price target raised to $125 from $115 at Leerink
Subscribe for More Information
07:31 EDTBSXBoston Scientific damages in case likely to be manageable, says Wells Fargo
Subscribe for More Information
05:57 EDTACTActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
05:47 EDTBSXStocks with implied volatility movement; BSX T
Stocks with implied volatility movement; Boston Scientific (BSX) 49, AT&T (T) 20 according to iVolatility.
January 21, 2015
12:30 EDTACTGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
09:16 EDTUNHOn The Fly: Pre-market Movers
Subscribe for More Information
07:22 EDTACTActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
06:06 EDTUNHUnitedHealth: Employer & Individual revenues decreased to $43B in 2014
Subscribe for More Information
06:05 EDTUNHUnitedHealth: ACA negatively impacted FY earnings by $1.00 per share
Subscribe for More Information
06:02 EDTUNHUnitedHealth sees FY15 EPS $6.00-$6.25, consensus $6.17
Subscribe for More Information
06:01 EDTUNHUnitedHealth reports Q4 EPS $1.55, consensus $1.50
Subscribe for More Information
January 20, 2015
15:21 EDTUNHNotable companies reporting before tomorrow's open
Subscribe for More Information
12:57 EDTUNHUnitedHealth volatility elevated into Q4 and outlook
Subscribe for More Information
09:02 EDTBAXBaxter receives FDA approval for PHOXILLUM solution
Subscribe for More Information
08:21 EDTLHLabCorp upgraded to Buy from Hold at Evercore ISI
Subscribe for More Information
08:16 EDTBAXMerrimack data of Phase 3 MM-398 NAPOLI-1 study supports development programs
Merrimack Pharmaceuticals (MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study of MM-398, also known as nal-IRI, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Merrimack and Baxter International's (BAX) biopharmaceutical business are collaborating on the development and commercialization of MM-398 outside of the United States and Taiwan. PharmaEngine holds the rights to commercialize MM-398 in Taiwan. Additionally, Merrimack presented preclinical and clinical data from studies of its investigational agents MM-141 and MM-151 in pancreatic and colorectal cancer, respectively. An investigator-sponsored study of MM-398 in colorectal cancer was also presented. The extended analyses for the global NAPOLI-1 Phase 3 trial presented at ASCO GI support the robustness of the overall survival benefit of MM-398 in combination with 5-fluorouracil, or 5-FU, and leucovorin presented in June 2014, at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer, or ESMO GI. The primary analysis, presented at ESMO GI, demonstrated a statistically significant advantage in overall survival with an unstratified hazard ratio of 0.67, and a median of 6.1 months for the combination of MM-398 plus 5-FU and leucovorin compared to 4.2 months in the control arm.
05:34 EDTACTActavis reports positive Phase III results for cariprazine
Gedeon Richter and Actavis announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. There were 101 patients randomized to cariprazine 3 to 9 mg per day and 99 randomized to placebo. The primary efficacy measure was time to first relapse during the double-blind period. There were 25 relapses in the cariprazine group versus 47 relapses in the placebo group. Treatment with cariprazine was associated with a 55% reduction in risk of relapse versus placebo.
January 16, 2015
10:47 EDTHUM, UNH, CNCBofA/Merrill healthcare facilities analyst analyst/industry conference call
Healthcare Facilities & Managed Care Analyst Bressler discusses the legislative and regulatory outlook for the industry for 2015 on an Analyst/Industry conference call to be held on January 23 at 2 pm.
January 15, 2015
13:10 EDTUNHUnitedHealth volatility elevated into Q4 and outlook
Subscribe for More Information
08:31 EDTUNHUnitedHealth, ProHEALTH announce new collaboration agreement
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use